SCF ubiquitin ligase-targeted therapies
暂无分享,去创建一个
[1] P. Cohen,et al. Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases? , 2010, Cell.
[2] A. Weissman,et al. HECT and RING finger families of E3 ubiquitin ligases at a glance , 2012, Journal of Cell Science.
[3] A. Ciechanover,et al. The 26 S Proteasome: From Basic Mechanisms to Drug Targeting* , 2009, The Journal of Biological Chemistry.
[4] T. Sixma,et al. Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. , 2011, Molecular cell.
[5] Hong Sun,et al. p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27 , 1999, Current Biology.
[6] J. Rain,et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells , 2009, Molecular Cancer Therapeutics.
[7] M. Pagano,et al. The After-Hours Mutant Reveals a Role for Fbxl3 in Determining Mammalian Circadian Period , 2007, Science.
[8] B. Rueda,et al. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer. , 2013, Endocrinology.
[9] Robert W. Taylor,et al. Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. , 2013, American journal of human genetics.
[10] Weiman Xing,et al. Crystal structure of mammalian cryptochrome in complex with a small molecule competitor of its ubiquitin ligase , 2013, Cell Research.
[11] Joseph S. Takahashi,et al. Circadian Mutant Overtime Reveals F-box Protein FBXL3 Regulation of Cryptochrome and Period Gene Expression , 2007, Cell.
[12] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[13] Marni J. Falk,et al. Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. , 2013, American journal of human genetics.
[14] J. Wade Harper,et al. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways , 2009, Nature Reviews Molecular Cell Biology.
[15] M. Pagano,et al. Regulation of the CRL4(Cdt2) ubiquitin ligase and cell-cycle exit by the SCF(Fbxo11) ubiquitin ligase. , 2013, Molecular cell.
[16] K. Nakayama,et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. , 2008, Blood.
[17] G. Roth,et al. Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells , 2010, BMC Biology.
[18] J. Toth,et al. A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. , 2012, Cell reports.
[19] Zhiwei Wang,et al. Roles of F-box proteins in cancer , 2014, Nature Reviews Cancer.
[20] Jeremy L. Jenkins,et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.
[21] L. Staudt. Oncogenic activation of NF-kappaB. , 2010, Cold Spring Harbor perspectives in biology.
[22] Bill B. Chen,et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation , 2013, Nature Immunology.
[23] D. Nixon,et al. HIV-1 Vpu Interference with Innate Cell-mediated Immune Mechanisms , 2012, Current HIV research.
[24] L. Kay,et al. Novel proteasome inhibitors to overcome bortezomib resistance. , 2011, Journal of the National Cancer Institute.
[25] M. Pagano,et al. SnapShot: F Box Proteins II , 2009, Cell.
[26] Alexander Varshavsky,et al. The ubiquitin system. , 1998, Annual review of biochemistry.
[27] Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .
[28] Andrew P. Weng,et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.
[29] Y. Kwaik,et al. Molecular Mimicry by an F-Box Effector of Legionella pneumophila Hijacks a Conserved Polyubiquitination Machinery within Macrophages and Protozoa , 2009, PLoS pathogens.
[30] Timothy Cardozo,et al. Systematic analysis and nomenclature of mammalian F-box proteins. , 2004, Genes & development.
[31] R. Deshaies,et al. Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase , 2013, ChemMedChem.
[32] A High‐Throughput Screening Method for Identification of Inhibitors of the Deubiquitinating Enzyme USP14 , 2012, Current protocols in chemical biology.
[33] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[34] Bill B. Chen,et al. Calmodulin Antagonizes a Calcium-Activated SCF Ubiquitin E3 Ligase Subunit, FBXL2, To Regulate Surfactant Homeostasis , 2011, Molecular and Cellular Biology.
[35] M. Mann,et al. Identification of the receptor component of the IκBα–ubiquitin ligase , 1998, Nature.
[36] Usha Narayanan,et al. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. , 2012, Cancer cell.
[37] W. Oyen,et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome , 2009, Neurology.
[38] M. Pagano,et al. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer , 2008, Nature Reviews Cancer.
[39] U. Narayanan,et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. , 2013, Cancer research.
[40] L. Staudt,et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.
[41] Michele Pagano,et al. SCFFbxl3 Ubiquitin Ligase Targets Cryptochromes at Their Cofactor Pocket , 2013, Nature.
[42] Dennis L. Buckley,et al. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. , 2014, Angewandte Chemie.
[43] Dawang Zhou,et al. Ubiquitin E3 Ligase CRL4CDT2/DCAF2 as a Potential Chemotherapeutic Target for Ovarian Surface Epithelial Cancer* , 2013, The Journal of Biological Chemistry.
[44] R. Deshaies,et al. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] A. Hoffmann,et al. Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma , 2012, Nature Cell Biology.
[46] M. Pagano,et al. Specific small molecule inhibitors of Skp2-mediated p27 degradation. , 2012, Chemistry & biology.
[47] F. Speleman,et al. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. , 2014, Cancer letters.
[48] P. Richardson,et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. , 2014, Blood.
[49] Kelvin H. Lee,et al. Serine phosphorylation is critical for the activation of ubiquitin-specific protease 1 and its interaction with WD40-repeat protein UAF1. , 2012, Biochemistry.
[50] V. Soldatenkov,et al. Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. , 1999, Cancer research.
[51] H. Walczak,et al. Linear ubiquitination: a newly discovered regulator of cell signalling. , 2013, Trends in biochemical sciences.
[52] H Strohmaier,et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. , 2001, Molecular cell.
[53] Y. Furuichi,et al. A novel small-molecule inhibitor of NF-kappaB signaling. , 2008, Biochemical and biophysical research communications.
[54] B. Clurman,et al. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation , 2008, Nature Reviews Cancer.
[55] Bill B. Chen,et al. Targeting F Box Protein Fbxo3 To Control Cytokine-Driven Inflammation , 2013, The Journal of Immunology.
[56] Bill B. Chen,et al. F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. , 2012, Blood.
[57] Christian Gieger,et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk , 2010, Nature Genetics.
[58] M. Gale,et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[59] P. Cao,et al. Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. , 2012, ACS medicinal chemistry letters.
[60] M. Pagano,et al. FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade , 2013, Nature Cell Biology.
[61] Marion Schmidt,et al. Regulation of proteasome activity in health and disease. , 2014, Biochimica et biophysica acta.
[62] K. Nakayama,et al. Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells , 2014, British Journal of Cancer.
[63] Yili Yang,et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. , 2007, Cancer research.
[64] F. Delom,et al. P97/CDC-48: proteostasis control in tumor cell biology. , 2013, Cancer letters.
[65] Y. Ye. Diverse functions with a common regulator: ubiquitin takes command of an AAA ATPase. , 2006, Journal of structural biology.
[66] Brett Larsen,et al. The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27 , 2001, Nature Cell Biology.
[67] R. Spang,et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.
[68] Robyn M. Kaake,et al. Signal-induced disassembly of the SCF ubiquitin ligase complex by Cdc48/p97. , 2012, Molecular cell.
[69] R. Deshaies,et al. NEDD8 links Cullin–Ring ubiquitin Ligase function to the p97 pathway , 2012, Nature Structural &Molecular Biology.
[70] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[71] Tohru Natsume,et al. Skp2-mediated degradation of p27 regulates progression into mitosis. , 2004, Developmental cell.
[72] Tatsuo Fukagawa,et al. An auxin-based degron system for the rapid depletion of proteins in nonplant cells , 2009, Nature Methods.
[73] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[74] S. Reed,et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. , 2007, Cancer research.
[75] L. Vassilev,et al. High-throughput screening for inhibitors of the Cks1-Skp2 interaction. , 2005, Methods in enzymology.
[76] S. Ševčíková,et al. Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma , 2014, Journal of cellular and molecular medicine.
[77] M. Hung,et al. Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression , 2013, Cell.
[78] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.
[79] M. Manns,et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. , 2004, Genes & development.
[80] Peter C. St. John,et al. Identification of Small Molecule Activators of Cryptochrome , 2012, Science.
[81] H. Handa,et al. Teratogenic effects of thalidomide: molecular mechanisms , 2011, Cellular and Molecular Life Sciences.
[82] K. Gustafson,et al. Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase β-TrCP1 , 2012, PloS one.
[83] Y. Li,et al. Chemical genetics of TOR identifies an SCF family E3 ubiquitin ligase inhibitor , 2010, Nature Biotechnology.
[84] Michael S. Cohen,et al. TrCP-and Rsk 1 / 2-Mediated Degradation of BimEL Inhibits Apoptosis , 2009 .
[85] Q. Gao,et al. Overactivated neddylation pathway as a therapeutic target in lung cancer. , 2014, Journal of the National Cancer Institute.
[86] N. Donato,et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. , 2010, Cancer research.
[87] Anindya Dutta,et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.
[88] Aaron Bouchie,et al. Nature Biotechnology's academic spinouts of 2014 , 2015, Nature Biotechnology.
[89] T. Katagiri,et al. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells , 2008, Oncogene.
[90] D. Beer,et al. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. , 2014, The Journal of clinical investigation.
[91] Frank M Boeckler,et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.
[92] O. Abdel-Wahab,et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. , 2013, Cancer cell.
[93] A. Ferrando,et al. The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability , 2013, Cell.
[94] S. Lonial,et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. , 2011, Blood.
[95] E. Álava,et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells , 2013, Oncogene.
[96] Steven P Gygi,et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. , 2007, Molecular cell.
[97] Leiliang Zhang,et al. Interplay between poxviruses and the cellular ubiquitin/ubiquitin‐like pathways , 2009, FEBS letters.
[98] Mark Manfredi,et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. , 2010, Blood.
[99] A. Jadhav,et al. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. , 2011, Chemistry & biology.
[100] M. Kitagawa,et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication , 2000, The EMBO journal.
[101] J. Pawlotsky. New hepatitis C therapies: the toolbox, strategies, and challenges. , 2014, Gastroenterology.
[102] M. Milhollen,et al. Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues , 2011, The Journal of Biological Chemistry.
[103] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[104] A. Ransick,et al. Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation* , 2003, Molecular & Cellular Proteomics.
[105] J. Toth,et al. Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells , 2013, PloS one.
[106] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[107] I. Flinn,et al. GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia , 2013, Current Hematologic Malignancy Reports.
[108] Mike Tyers,et al. E2 enzyme inhibition by stabilization of a low affinity interface with ubiquitin , 2013, Nature chemical biology.
[109] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[110] Bill B. Chen,et al. Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis , 2013, Cell Death and Disease.
[111] Peter G. Smith,et al. The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. , 2010, Genes & cancer.
[112] C. Rommel,et al. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. , 2011, Cancer discovery.
[113] A. Bouchie,et al. Nature Biotechnology's academic spinouts of 2013 , 2014, Nature Biotechnology.
[114] C. Stevens,et al. Aquaporin 4 and glymphatic flow have central roles in brain fluid homeostasis , 2021, Nature Reviews Neuroscience.
[115] M. Gregory,et al. c-Myc Proteolysis by the Ubiquitin-Proteasome Pathway: Stabilization of c-Myc in Burkitt's Lymphoma Cells , 2000, Molecular and Cellular Biology.
[116] Mike Tyers,et al. An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme , 2011, Cell.
[117] Min Jae Lee,et al. Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.
[118] S. Demo,et al. Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells , 2011, PloS one.
[119] Zhihao Zhuang,et al. A noncanonical cysteine protease USP1 is activated through active site modulation by USP1-associated factor 1. , 2012, Biochemistry.
[120] Peter Lassota,et al. Bioluminescent imaging of Cdk2 inhibition in vivo , 2004, Nature Medicine.
[121] M. Pagano,et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. , 2005, Molecular cell.
[122] Dmitri A. Nusinow,et al. Cryptochrome Mediates Circadian Regulation of cAMP Signaling and Hepatic Gluconeogenesis , 2010, Nature Medicine.
[123] M. Blagosklonny. Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions , 2004, Cell cycle.
[124] Christopher R. Jones,et al. An hPer2 Phosphorylation Site Mutation in Familial Advanced Sleep Phase Syndrome , 2001, Science.
[125] J Wade Harper,et al. Building and remodelling Cullin–RING E3 ubiquitin ligases , 2013, EMBO reports.
[126] Xiaodong Cai,et al. Yeast Augmented Network Analysis (YANA): a new systems approach to identify therapeutic targets for human genetic diseases , 2014, F1000Research.
[127] L. Chin,et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers , 2007, Nature.
[128] Atsushi Hirao,et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. , 2013, Cancer cell.
[129] M. Gale,et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. , 2005, Molecular cell.
[130] L. Larsson,et al. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.
[131] Michele Pagano,et al. SCFFbxl3 Controls the Oscillation of the Circadian Clock by Directing the Degradation of Cryptochrome Proteins , 2007, Science.
[132] Michal Sharon,et al. Mechanism of auxin perception by the TIR1 ubiquitin ligase , 2007, Nature.
[133] Bill B. Chen,et al. F box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest , 2011, Oncogene.
[134] F. Chan,et al. Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer , 2009, British Journal of Cancer.
[135] E. Álava,et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma , 2012, Oncogene.
[136] Parantu K. Shah,et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.
[137] I. Aifantis,et al. The ubiquitous nature of cancer: the role of the SCFFbw7 complex in development and transformation , 2010, Oncogene.
[138] J. Vincent,et al. Truncation of the E3 ubiquitin ligase component FBXO31 causes non-syndromic autosomal recessive intellectual disability in a Pakistani family , 2014, Human Genetics.
[139] K. Birkenkamp-Demtroder,et al. MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. , 2012, Carcinogenesis.
[140] D. Amadori,et al. Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer , 2014, Expert opinion on pharmacotherapy.
[141] A. Iwama,et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. , 2008, Genes & development.
[142] S. Keir,et al. Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.
[143] A. McKenna,et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.
[144] Wilhelm Krek,et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells , 1999, Nature Cell Biology.
[145] C. Crews,et al. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.
[146] A. Fersht,et al. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. , 2010, Chemistry & biology.
[147] M. Mattern,et al. Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors☆ , 2012, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.
[148] Anindya Dutta,et al. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. , 2013, Molecular cell.
[149] René Bernards,et al. A Genomic and Functional Inventory of Deubiquitinating Enzymes , 2005, Cell.
[150] A. VanHook. More Than a Protease , 2012, Science Signaling.
[151] Hua Li,et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. , 2012, Cancer research.
[152] M. Ohh,et al. NEDD8 pathways in cancer, Sine Quibus Non. , 2011, Cancer cell.
[153] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[154] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[155] K. Wilner,et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) , 2011, British Journal of Cancer.
[156] K. Hofmann,et al. Activating the ubiquitin family: UBA6 challenges the field. , 2008, Trends in biochemical sciences.
[157] Timothy Cardozo,et al. The SCF ubiquitin ligase: insights into a molecular machine , 2004, Nature Reviews Molecular Cell Biology.
[158] L. Staudt,et al. 4924 , a NEDD 8-activating enzyme inhibitor , is active in diffuse large B-cell lymphoma models : rationale for treatment of NF-B – dependent lymphoma * , 2010 .
[159] Nadine H. Elowe,et al. An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase , 2010, Nature Biotechnology.
[160] Michele Pagano,et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas , 2012, Nature.
[161] Michael S. Cohen,et al. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. , 2009, Molecular cell.
[162] S. Eckhardt,et al. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. , 2014, Pharmacology & therapeutics.
[163] Michele Pagano,et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.
[164] Eric S. Lander,et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.
[165] Donna M. Martin,et al. Macrocerebellum, epilepsy, intellectual disability, and gut malrotation in a child with a 16q24.1–q24.2 contiguous gene deletion , 2014, American journal of medical genetics. Part A.
[166] Christopher E. Berndsen,et al. New insights into ubiquitin E3 ligase mechanism , 2014, Nature Structural &Molecular Biology.
[167] R. Deshaies,et al. RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.
[168] Michele Pagano,et al. Mechanisms and function of substrate recruitment by F-box proteins , 2013, Nature Reviews Molecular Cell Biology.
[169] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[170] Hung-Wei Pan,et al. Role of L2DTL, Cell Cycle-Regulated Nuclear and Centrosome Protein, in Aggressive HepatocellularCarcinoma , 2006, Cell cycle.
[171] P. Cohen,et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.
[172] A. Isacchi,et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. , 2013, Nature chemical biology.
[173] R. Chung,et al. Antiviral treatment of hepatitis C , 2014, BMJ : British Medical Journal.
[174] M. Rapé,et al. The Ubiquitin Code , 2012, Annual review of biochemistry.
[175] B. Nicholson,et al. The Multifaceted Roles of USP7: New Therapeutic Opportunities , 2011, Cell Biochemistry and Biophysics.
[176] X. Deng,et al. The COP9 signalosome: more than a protease. , 2008, Trends in biochemical sciences.
[177] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.